The Joint Corp. Stock News

- Grows 2021 Revenue 38%, System-wide Sales 39%, and System-wide Comp Sales 29%, Compared to 2020 - - Sold 156 Franchise Licenses, Compared to 121 in 2020 - - Opened 130 Clinics, Including 20 Greenfi

- Grows 2021 Revenue 38%, System-wide Sales 39%, and System-wide Comp Sales 29%, Compared to 2020 - - Sold 156 Franchise Licenses, Compared to 121 in 2020 - - Opened 130 Clinics, Including 20 Greenfields, Bringing the Total Corporate Count to 96 at Year End -

The Joint Corp. (JYNT) delivered earnings and revenue surprises of -87.50% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Joint Corp (JYNT) CEO Peter Holt on Q4 2021 Results - Earnings Call Transcript

- Grows 2021 Revenue 38%, System-wide Sales 39%, and System-wide Comp Sales 29%, Compared to 2020 - - Sold 156 Franchise Licenses, Compared to 121 in 2020 - - Opened 130 Clinics, Including 20 Greenfi

The Joint Corp. (JYNT) delivered earnings and revenue surprises of -87.50% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Joint (NASDAQ:JYNT) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is $0.04 (-94.4% Y/Y) and the consensus…

Teladoc Health, Albireo Pharma and The Joint Corp are included in this blog.

In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.

Medtronic (MDT) might report low procedure volumes in the fiscal third quarter in markets where its technologies are used in more deferrable procedures.

The Joint Corp. (JYNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teladoc Health's (TDOC) Q4 results are expected to gain from high sales and visits volume.

The consensus price target hints at an 84.3% upside potential for The Joint Corp. (JYNT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings

Mednax (MD) issues senior notes, and a new revolving credit facility coupled with a term loan remains in place, which is aimed at reducing MD's debt level and associated interest expenses.